Veru Inc.

VERU

$2.65

-3.64%

2026-09-03 16:00:00 EDT-$0.10

Healthcare

Biotechnology

NASDAQ

Active Trading

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets ...

Price Action of VERU

$2.65

-3.64%-$0.10

High—

Low—

52W High-42.3%

Rel. vol—

Interval

Range2.8h

Volume—SMA5SMA10

—

Veru Inc. (NASDAQ: VERU) is a biopharmaceutical company headquartered in Miami, Florida, originally incorporated in 1971 as The Female Health Company and renamed in July 2017. The company is led by CEO Dr. Mitchell S. Steiner, and it focuses on developing innovative therapeutics for oncology and other serious diseases. In ...Veru Inc. (NASDAQ: VERU) is a biopharmaceutical company headquartered in Miami, Florida, originally incorporated in 1971 as The Female Health Company and renamed in July 2017. The company is led by CEO Dr. Mitchell S. Steiner, and it focuses on developing innovative therapeutics for oncology and other serious diseases. In its commercial business, Veru markets the FC2 internal condom, which provides dual protection against unintended pregnancy and sexually transmitted infections. This product is sold globally to government health departments, UN organizations, non-profits, and commercial distributors. The company's development pipeline is robust, with a strong focus on oncology. Key drug candidates include Enobosarm, an oral selective androgen receptor agonist in Phase III trials for AR+, ER+, HER2- metastatic breast cancer, and Sabizabulin, a cytoskeleton disruptor in Phase IIb for the same indication. A combination of Enobosarm and abemaciclib is also in Phase III for metastatic breast cancer. For triple-negative breast cancer, a combination of Sabizabulin and Enobosarm is in Phase II. In prostate cancer, Sabizabulin is in Phase II for metastatic castration-resistant prostate cancer, and VERU-100, a GnRH antagonist, is in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru investigates other conditions: Zuclomiphene Citrate for hot flashes, Sabizabulin for SARS-CoV-2 in high-risk patients (Phase III), and a novel formulation for lower urinary tract symptoms in men. Financially, Veru has a market cap of approximately $44.8 million, with negative profitability metrics typical for a clinical-stage biotech. The company has a current ratio of 4.423, indicating strong liquidity, and a low debt-to-equity ratio of 0.095. Research and development expenses are significant, and the company relies on equity financing. The stock has a beta of -1.196, showing low volatility relative to the market. Employee count is around 20, reflecting a lean operation. The company emphasizes innovation in cancer treatment and has partnerships and collaborations to advance its pipeline. Despite financial losses, Veru's pipeline holds promise, and its commercial product provides some revenue. The company's future hinges on successful clinical trials and regulatory approvals.ExpandCollapse

Founded

1971

Employees

CEO

Mitchell S. Steiner

Full Name

Veru Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-45.89%

Market Cap

$0.04B

Current Ratio

4.42

WACC

5.39%

ROIC

-88.61%

Contact Information

https://www.verupharma.com

305 509 6897

2916 North Miami Avenue, Miami, FL 33127

Key Metrics of VERU

Snapshot

Latest / TTM · 6 periods

Market Cap

$42.53M

ROCE

-62.2%

EV / EBITDA

-0.79x

+50.1% YoY

FCF Yield

-61.2%

-7.2% YoY

Cash Conversion Cycle

-11067.0d

Current Ratio

4.42

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of VERU

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-4.41x

n/a

Debt / Equity

0.09

n/a

Current Ratio

4.42

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of VERU

Upcoming

Sep 30, 2026In 26 days
FY2026 · Estimated annual results
Est. EPS $-1.01 · Revenue $2.67M · 1 analysts
Sep 30, 2027
FY2027 · Estimated annual results
Est. EPS $-0.98 · Revenue $4.00M · 1 analysts
Sep 30, 2028
FY2028 · Estimated annual results
Est. EPS $-0.66 · Revenue $50.00M · 2 analysts
Sep 30, 2029
FY2029 · Estimated annual results
Est. EPS $-0.76 · Revenue $125.00M · 1 analysts

Recent history

Aug 10, 2026
Q3 FY2026 · Results reported
EPS $-0.30 · Revenue $0.00
View filing
May 13, 2026
Q2 FY2026 · Results reported
EPS $-0.13 · Revenue $0.00
View filing
Feb 11, 2026
Q1 FY2026 · Results reported
EPS $-0.26 · Revenue $0.00
View filing
Dec 17, 2025
FY2025 · Annual results
EPS $-1.55 · Revenue $0.00
View filing
Aug 12, 2025
Q3 FY2025 · Results reported
EPS $-0.50 · Revenue $0.00
View filing
May 8, 2025
Q2 FY2025 · Results reported
EPS $-0.54 · Revenue $0.00
View filing

Financial Statements of VERU

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	-100.0%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-22.7M	+39.9%	-154.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-30.0M	-37.6%	+38.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	17.0%	-60.4%	+16.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.43x	-18.1%	-28.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$29.8M	-50.6%	-14.1%

Actual vs Estimate

A Sep 30Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.55 vs -1.13	-37.2%	-0.30 vs -0.32	+6.3%
Revenue Surprise	$0 vs $2.8M	-100.0%	$0 vs $1.7M	-100.0%

Insider Transactions of VERU

Acquisitions (A)

Since Dec 5, 2025

Disposals (D)

Since Dec 5, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 13, 2026	BARNETTE K GARY	officer: Chief Scientific Officer	Common Stock	A	1,800	$2.69
May 4, 2026	STEINER MITCHELL SHUSTER	director, officer: President and CEO	Common Stock Option	A	604,000	$2.25
May 4, 2026	Greco Michele	officer: Chief Admin Officer and CFO	Common Stock Option	A	164,000	$2.25
May 4, 2026	Katzovitz Loren Mark	director	Common Stock Option	A	102,000	$2.25
May 4, 2026	Hyun Grace	director	Common Stock Option	A	97,000	$2.25

Earnings Call Transcript of VERU

1 transcript segments

Q3 2026

Unknown Speaker

Operator: Good morning, ladies and gentlemen, and welcome to Veru Inc.'s Investors Conference Call. [Operator Instructions] Please note that this event is being recorded. I would now like to turn the conference call over to Mr. Sam Fisch, Veru Inc.'s Executive Director, Investor Relations and Corporate Communications. Please go ahead. Samuel Fisch: The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and 10-K SEC filings as well as in our press releases from time to time. I would now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc.'s Chairman, CEO and President. Mitchell Steiner: Good morning. With me on this morning's call are Dr. Gary Barnette, our Chief Scientific Officer; Michele Greco, Chief Financial Officer and Chief Administrative Officer; Phil Greenberg, our General Counsel; and Sam Fisch, Executive Director of Investor Relations and Corporate Communications. Thank you for joining us in our third quarter fiscal year 2026 earnings call. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two novel small molecules: enobosarm and sabizabulin. The first one, enobosarm, is an oral selective androgen receptor modulator SARM and is being developed as a next-generation drug that when combined with a GLP-1 receptor agonist makes weight reduction more tissue selective for fat loss and preservation of lean mass and physical function which is intended to lead to greater weight loss compared to a GLP-1 receptor agonist treatment alone with a focus on older patients with obesity. Our second asset, sabizabulin, is a microtubule disruptor is being developed as a broad anti-inflammatory agent to reduce vascular plaque inflammation to slow the progression or promote the regression of atherosclerotic cardiovascular disease. This morning, we will focus on the update of the clinical development progress of enobosarm in our obesity program. We will also provide financial highlights of fiscal 2026 third quarter ended June 30, 2026. GLP-1s have been known to produce significant weight loss in patients who are overweight or have obesity. Unfortunately, this weight loss is tissue non-selective with a significant indiscriminate loss of both lean mass and fat mass. Of the total weight loss up to 50% is …

Leadership Team of VERU

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Mitchell S. Steiner	Chairman, President & Chief Executive Officer	USD 1,486,367	—	1961	Active
K. Gary Barnette	Chief Scientific Officer	USD 896,079	—	1968	Active
Harry Fisch	Vice Chairman & Chief Corporate Officer	USD 724,488	—	1959	Active
Michele Greco	Chief Financial Officer & Chief Administrative Officer	USD 493,703	Female	1959	Active
Martin Tayler	Executive Vice President of FC2 Global Operations	USD 180,512	Male	1969	Active
Domingo Rodriguez	Executive Vice President of Global Clinical Operations	—	—	1962	Active
Samuel Fisch	Executive Director of Investor Relations & Corporate Communications	—	Male	—	Active
Gary Bird	Executive Vice President of Quality & Regulatory Affairs	—	—	—	Active
Kevin J. Gilbert	Executive Vice President of Corporate Development	—	Male	—	Active
Philip R. Greenberg	Executive VP, General Counsel & Secretary	—	Male	—	Active

Recent News of VERU

Seeking Alpha8/10/2026Neutral

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

GlobeNewsWire8/10/2026Neutral

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

GlobeNewsWire8/4/2026Neutral

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --

GlobeNewsWire8/3/2026Neutral

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.

GlobeNewsWire7/30/2026Neutral

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Canaccord Genuity's 46th Annual Growth Conference, in Boston, Massachusetts, on August 12, 2026 at 2:00 pm – 2:25 pm Eastern Daylight Time.

Historical Employee Count of VERU

Current

Change

-90.48%

Minimum

Maximum

252

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Sep 30, 2025	20	10-K	Dec 17, 2025	View
Sep 30, 2024	210	10-K	Dec 16, 2024	View
Sep 30, 2023	189	10-K	Dec 8, 2023	View
Sep 30, 2022	233	10-K	Dec 5, 2022	View
Sep 30, 2021	252	10-K	Dec 2, 2021	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Veru Inc.